WuXi Reports Record Revenues, CapEx Spending

WuXi PharmaTech reported Q3 revenues were up 18% to $173.6 million, a record, while GAAP earnings per were higher by a smaller 8% at $0.45. The company has "strong momentum," according to Dr. Ge Li, Chairman and CEO. To keep growing, it increased Capital Expenditures from $56 million last year to $100 million in 2014, and will spend even more next year to increase manufacturing capacity, WuXi's fastest growing business sector. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.